Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Report Ocean is delighted to unveil an exhaustive analysis of the Philippines Diabetes Devices Market, presenting a detailed exploration of its various dimensions from 2018 to 2032. Our in-depth study ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an ...

Trump named Alex Azar, a top executive at Eli Lilly, to head Health and Human Services. (Under Azar, Eli Lilly tripled the price of its top-selling insulin drug.) But President Joe Biden's Inflation ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...

Shares of Medtronic (NYSE: MDT) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices giant had some weakness in recent years amid disappointing trends from its ...

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...